2022 annual financial data
Prelude Therapeutics 2022 Net income growth
Direct answer
Net income growth was 3.11%.
Operating income was -123,540,000 USD and net income was -107,336,000 USD.
Operating cash flow was -83,729,000 USD.
Get free Prelude Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -123,540,000 USD
- Net income
- -107,336,000 USD
- Operating cash flow
- -83,729,000 USD